367259-04-9

Basic information

• Product Name: (3-methoxy-5-hydroxy-phenyl)-acetic acid methyl ester
• Synonyms: (3-methoxy-5-hydroxy-phenyl)-acetic acid methyl ester
• CAS NO: 367259-04-9
• Molecular Weight: 196.203
• Mol File: 367259-04-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 332.3±27.0 °C(Predicted)
• Density: 1.191±0.06 g/cm3(Predicted)
• CAS DataBase Reference: (3-methoxy-5-hydroxy-phenyl)-acetic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (3-methoxy-5-hydroxy-phenyl)-acetic acid methyl ester(367259-04-9)
• EPA Substance Registry System: (3-methoxy-5-hydroxy-phenyl)-acetic acid methyl ester(367259-04-9)

Safety Data

• Hazardous Substances Data: 367259-04-9(Hazardous Substances Data)

Upstream product

• 50637-26-8 methyl 3-(benzyloxy)-5-methoxybenzoate 
• 50637-28-0 (3-(benzyloxy)-5-methoxyphenyl)methanol 
• 2150-44-9 1-carbomethoxy-3,5-dihydroxybenzene 
• 628330-11-0 (3-benzyloxy-5-methoxyphenyl)acetonitrile 
• 4670-09-1 2-(3,5-dihydroxyphenyl)acetic acid 
• 4670-10-4 (3,5-dimethoxyphenyl)acetic acid 
• 4724-10-1 methyl 2-(3,5-dihydroxyphenyl)acetate 
• 74-88-4 methyl iodide 
• 628330-12-1 methyl (3-benzyloxy-5-methoxyphenyl)acetate 

Downstream Products

• 1056453-99-6 [3-(3-bromo-phenoxy)-5-methoxy-phenyl]-acetic acid methyl ester 
• 1056453-39-4 (3-methoxy-5-trifluoromethanesulfonyloxy-phenyl)-acetic acid methyl ester 
• 1056986-94-7 C₁₇H₁₄ClNO₄ 

Relevant articles and documents

First total synthesis of medicinally important 3,4,7-trimethoxy-9,10-dihydrophenanthrene-1,5-diol

The first total synthesis was successfully achieved for biologically active 9,10-dihydrophenanthrene-1,5-diol. The key features of our synthetic approach are Perkin condensation, followed by bromination, palladium mediated intramolecular C-C bond coupling, and selective isopropyl ether cleavage. Synthesized compounds were purified and characterized by IR, 1HNMR, 13CNMR and HRMS/LC-MS.

ARYLACETATE DERIVATIVE HAVING ISOXAZOLE SKELETON

A compound of the formula (I): pharmaceutically acceptable salt or solvate thereof, wherein Y is a group of the formula: wherein Ring A is optionally substituted aryl or optionally substituted heteroaryl, X3 is COOR17 or the like Y i

Non-nucleoside reverse transcriptase inhibitors

The present invention provides compounds for treating or preventing an HIV infection, or treating AIDS or ARC comprising administering a compound according to formula I where Ar, R1-R5, R7a, R7b, R7c, R8-R10, X1, X2 m, n, o and p are as defined herein.